Since the FoB's are being named uniquely once a patient starts on Brand/generic do you envision less switching (then traditional generics) because of potential safety issues (immuniginicity)?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.